9 Meters Biopharma, Inc. (NMTRQ)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
9 Meters Biopharma, Inc. (NMTRQ) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 48/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 20269 Meters Biopharma, Inc. (NMTRQ) Gesundheitswesen & Pipeline-Uebersicht
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on rare digestive diseases, including short bowel syndrome, and gastrointestinal conditions. Its lead product, Vurolenatide, is in Phase 3 trials. The company filed for Chapter 7 liquidation in 2023, impacting its future operations and potential for drug development within the competitive biotechnology sector.
Investmentthese
The investment thesis for 9 Meters Biopharma, Inc. is significantly impacted by its Chapter 7 liquidation filing in July 2023. With a market capitalization of $0.00B and a negative ROE of -375.6%, the company's financial viability is uncertain. The high beta of 10.00 indicates extreme volatility. While Vurolenatide was in Phase 3 trials, the bankruptcy proceedings cast doubt on its future development and potential revenue generation. Investors should be aware of the high risks associated with companies undergoing liquidation, including the potential loss of investment.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $0.00B indicates the company's distressed financial state.
- ROE of -375.6% reflects significant losses and financial instability.
- Free Cash Flow of $-0.00B highlights the company's inability to generate positive cash flow.
- Beta of 10.00 indicates extremely high volatility compared to the market average.
- Chapter 7 bankruptcy filing on July 17, 2023, signals the company's intent to liquidate its assets.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary drug candidates in clinical development.
- Focus on rare and unmet medical needs.
- Licensing agreements with other companies.
- Experienced management team in drug development.
Schwaechen
- Chapter 7 bankruptcy filing.
- Limited financial resources.
- High dependence on clinical trial outcomes.
- Negative ROE and Free Cash Flow.
Katalysatoren
- Ongoing: Potential for asset sales during liquidation proceedings.
- Ongoing: Legal proceedings related to bankruptcy.
- Ongoing: Potential for restructuring or acquisition of assets.
Risiken
- Ongoing: Chapter 7 bankruptcy leading to complete loss of investment.
- Potential: Delisting from the OTC market.
- Potential: Legal claims from creditors.
- Potential: Loss of intellectual property rights.
- Potential: Negative impact on reputation and future business prospects.
Wachstumschancen
- Advancement of Vurolenatide: Vurolenatide, a long-acting injectable glucagon-like-peptide-1 (GLP-1), was in Phase 3 clinical trials for treating short bowel syndrome (SBS). Successful completion of these trials and subsequent regulatory approval could have addressed a significant unmet need in the SBS market, estimated to reach $2.3 billion by 2028. However, the company's bankruptcy filing jeopardizes this potential growth driver.
- Development of NM-136: NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders, represented a potential expansion into a large and growing market. The global obesity market is projected to reach $40 billion by 2030, driven by increasing prevalence of obesity and related comorbidities. However, the bankruptcy filing casts doubt on the continued development of this asset.
- Expansion of NM-102: NM-102, a small molecule peptide designed to prevent antigens from trafficking into systemic circulation, could have addressed various autoimmune and inflammatory conditions. The market for autoimmune disease treatments is substantial, estimated at $60 billion globally. Further development of NM-102 could have opened new avenues for growth, but the bankruptcy filing impacts its future.
- Partnered Product Larazotide: Larazotide, an 8-amino acid peptide in Phase 2 clinical trials for multi-system inflammatory syndrome, represented a partnered opportunity. Positive trial results and subsequent commercialization could have generated revenue through royalties or milestone payments. However, the bankruptcy filing introduces uncertainty regarding the future of this partnership and the development of Larazotide.
- Licensing Agreements: 9 Meters Biopharma had licensing agreements with companies like Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. These agreements could have provided access to novel technologies and therapeutic candidates, potentially fueling future growth. However, the bankruptcy filing may impact the validity and continuation of these agreements.
Chancen
- Potential for successful clinical trial results.
- Partnerships for further drug development.
- Market growth in rare digestive diseases.
- Advancements in biotechnology and drug delivery.
Risiken
- Regulatory hurdles and approval delays.
- Competition from other pharmaceutical companies.
- Clinical trial failures.
- Economic downturn impacting healthcare spending.
Wettbewerbsvorteile
- Proprietary drug candidates targeting specific unmet needs.
- Intellectual property protection through patents and exclusivity.
- Clinical trial data supporting efficacy and safety.
- Licensing agreements providing access to novel technologies.
Ueber NMTRQ
9 Meters Biopharma, Inc. was a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for rare and unmet needs in digestive diseases. Founded with the mission to improve the lives of patients with gastrointestinal disorders, the company focused on developing treatments for conditions like short bowel syndrome (SBS) and other debilitating digestive ailments. Its lead product candidate, Vurolenatide, a long-acting injectable glucagon-like-peptide-1 (GLP-1), reached Phase 3 clinical trials for the treatment of SBS, representing a significant milestone in its development pipeline. In addition to Vurolenatide, 9 Meters Biopharma was also developing NM-136, a humanized monoclonal antibody for obesity and related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. The company also had a partnered product, Larazotide, an 8-amino acid peptide in Phase 2 trials for multi-system inflammatory syndrome. 9 Meters Biopharma operated through licensing agreements with companies like Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. Headquartered in Raleigh, North Carolina, the company's operations came to a halt when it filed a voluntary petition for liquidation under Chapter 7 bankruptcy on July 17, 2023.
Was das Unternehmen tut
- Develops treatments for rare digestive diseases.
- Focuses on gastrointestinal conditions with unmet needs.
- Develops therapies for debilitating disorders.
- Lead product candidate was Vurolenatide for short bowel syndrome.
- Developing NM-136 for obesity and obesity-related disorders.
- Developing NM-102 to prevent antigens from trafficking into systemic circulation.
- Developing NM-003 for prevention of acute graft versus host disease.
- Partnered product Larazotide for multi-system inflammatory syndrome.
Geschaeftsmodell
- Develops pharmaceutical products through internal research and development.
- Out-licenses or partners with other companies for development and commercialization.
- Generates revenue through potential future sales of approved drugs.
- Relies on licensing agreements for technology and product development.
Branchenkontext
9 Meters Biopharma operated within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant risks of clinical trial failures. Companies in this sector often focus on niche markets and rare diseases to gain regulatory advantages and market exclusivity. However, the company's bankruptcy filing reflects the challenges faced by smaller biotech firms in securing funding and navigating the complexities of drug development. Competitors like ADYX and BIMI operate in similar therapeutic areas, highlighting the competitive pressure in the market.
Wichtige Kunden
- Patients with rare digestive diseases.
- Healthcare providers treating gastrointestinal conditions.
- Hospitals and clinics specializing in digestive disorders.
- Pharmaceutical companies through licensing and partnership agreements.
Finanzdaten
Chart & Info
9 Meters Biopharma, Inc. (NMTRQ) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer NMTRQ verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer NMTRQ.
Kursziele
Wall-Street-Kurszielanalyse fuer NMTRQ.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von NMTRQ auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Peter H. R. Green
CEO
Peter H. R. Green served as the CEO of 9 Meters Biopharma, Inc. His background includes experience in managing pharmaceutical companies and overseeing the development of clinical-stage drug candidates. He has a track record in the biotechnology industry, with expertise in corporate strategy, business development, and clinical operations. His leadership was focused on advancing the company's pipeline of therapies for rare digestive diseases.
Erfolgsbilanz: Under Peter H. R. Green's leadership, 9 Meters Biopharma focused on advancing its lead product candidate, Vurolenatide, through Phase 3 clinical trials. He oversaw the development of other drug candidates, including NM-136, NM-102, and NM-003. However, his tenure concluded with the company filing for Chapter 7 bankruptcy, impacting the future of these programs.
NMTRQ OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that 9 Meters Biopharma, Inc. did not meet the requirements for the higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, be undergoing bankruptcy, or have regulatory issues. Investing in OTC Other stocks carries significantly higher risks compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of stringent listing standards and regulatory oversight. The OTC Other tier often includes shell companies, defunct companies, and companies with questionable business practices.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for fraud or manipulation.
- Bankruptcy proceedings.
- Lack of regulatory oversight.
- Verify the company's legal status and registration.
- Review any available financial statements.
- Assess the company's assets and liabilities.
- Investigate the background of the management team.
- Determine the reasons for trading on the OTC Other tier.
- Understand the risks associated with investing in bankrupt companies.
- Consult with a financial advisor.
- Previous clinical-stage development of drug candidates.
- Prior licensing agreements with other companies.
- Historical focus on addressing unmet medical needs.
- Listing on OTC market (however, this is a weak signal due to the OTC Other tier)
NMTRQ Healthcare Aktien-FAQ
What are the key factors to evaluate for NMTRQ?
9 Meters Biopharma, Inc. (NMTRQ) currently holds an AI score of 48/100, indicating low score. Key strength: Proprietary drug candidates in clinical development.. Primary risk to monitor: Ongoing: Chapter 7 bankruptcy leading to complete loss of investment.. This is not financial advice.
How frequently does NMTRQ data refresh on this page?
NMTRQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NMTRQ's recent stock price performance?
Recent price movement in 9 Meters Biopharma, Inc. (NMTRQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary drug candidates in clinical development.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NMTRQ overvalued or undervalued right now?
Determining whether 9 Meters Biopharma, Inc. (NMTRQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NMTRQ?
Before investing in 9 Meters Biopharma, Inc. (NMTRQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding NMTRQ to a portfolio?
Potential reasons to consider 9 Meters Biopharma, Inc. (NMTRQ) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary drug candidates in clinical development.. Additionally: Focus on rare and unmet medical needs.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of NMTRQ?
Yes, most major brokerages offer fractional shares of 9 Meters Biopharma, Inc. (NMTRQ) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track NMTRQ's earnings and financial reports?
9 Meters Biopharma, Inc. (NMTRQ) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for NMTRQ earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- The company's bankruptcy proceedings introduce significant uncertainty.